Vuity vs Tepezza
A side-by-side look at two eye health medications advertised on TV. Informational only — not medical advice.
| US Vuity | US Tepezza | |
|---|---|---|
| Generic name | pilocarpine ophthalmic | teprotumumab |
| Drug class | Cholinergic Muscarinic Agonist (Eye Drop) | IGF-1R Inhibitor (Biologic) |
| Treats | Age-related blurry near vision (presbyopia) | Thyroid eye disease |
| Category | Eye Health | Eye Health |
| Manufacturer | AbbVie (Allergan) | Amgen |
| Year approved | 2021 | 2020 |
| FDA warning | No boxed warning | Moderate warnings |
| Est. TV ad spend | $70M | — |
| Common side effects | Headache, Eye redness, Trouble with night vision, Eye pain | Muscle spasms, Nausea, Hair loss, Hearing problems |
Frequently asked questions
Is Vuity or Tepezza better?
Neither is universally "better." Vuity (pilocarpine ophthalmic) and Tepezza (teprotumumab) are both used for eye health, but the right choice depends on your medical history, insurance and your doctor's guidance. This comparison is informational only.
What's the difference between Vuity and Tepezza?
Vuity is a Cholinergic Muscarinic Agonist (Eye Drop) made by AbbVie (Allergan), while Tepezza is a IGF-1R Inhibitor (Biologic) made by Amgen. See the table above for a side-by-side breakdown.
Which one spends more on TV ads?
Vuity has the larger estimated TV advertising budget of the two.